A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.

[1]  David R. Jones,et al.  Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers , 2021, Nature.

[2]  Sri Krishna,et al.  A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types , 2021, Nature Cancer.

[3]  P. Van Loo,et al.  Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition , 2021, Cell.

[4]  Congjian Xu,et al.  CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer , 2021, Journal for ImmunoTherapy of Cancer.

[5]  G. Altan-Bonnet,et al.  Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer , 2020, Science.

[6]  Jifeng Yu,et al.  Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome , 2020, Scientific Reports.

[7]  A. Regev,et al.  Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment. , 2020, Immunity.

[8]  S. H. van der Burg,et al.  CD39 Identifies the CD4+ Tumor-Specific T-cell Population in Human Cancer , 2020, Cancer Immunology Research.

[9]  H. Rammensee,et al.  Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire , 2020, Nature Reviews Clinical Oncology.

[10]  S. Teichmann,et al.  Malat1 Suppresses Immunity to Infection through Promoting Expression of Maf and IL-10 in Th Cells , 2020, The Journal of Immunology.

[11]  Ash A. Alizadeh,et al.  Functional significance of U2AF1 S34F mutations in lung adenocarcinomas , 2019, Nature Communications.

[12]  E. Wherry,et al.  Defining ‘T cell exhaustion’ , 2019, Nature Reviews Immunology.

[13]  Paul J. Hoffman,et al.  Comprehensive Integration of Single-Cell Data , 2018, Cell.

[14]  C. Meisel,et al.  Killer-like receptors and GPR56 progressive expression defines cytokine production of human CD4+ memory T cells , 2019, Nature Communications.

[15]  E. Wherry,et al.  CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. , 2019, Annual review of immunology.

[16]  G. Linette,et al.  A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma , 2019, Nature Medicine.

[17]  F. Hodi,et al.  Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade , 2019, Nature Immunology.

[18]  I. Amit,et al.  Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma , 2019, Cell.

[19]  Daniel E. Speiser,et al.  Intratumoral Tcf1+PD‐1+CD8+ T Cells with Stem‐like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy , 2019, Immunity.

[20]  J. Gartner,et al.  Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. , 2019, Cancer discovery.

[21]  S. Campello,et al.  Drp1 Controls Effective T Cell Immune-Surveillance by Regulating T Cell Migration, Proliferation, and cMyc-Dependent Metabolic Reprogramming , 2018, Cell reports.

[22]  Paul J. Hoover,et al.  Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma , 2018, Cell.

[23]  B. Fox,et al.  Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors , 2018, Nature Communications.

[24]  C. Klein,et al.  A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade , 2018, Nature Medicine.

[25]  J. Gartner,et al.  Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer , 2018, Nature Medicine.

[26]  M. Fehlings,et al.  Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates , 2018, Nature.

[27]  E. Wherry,et al.  Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155. , 2018, Cell reports.

[28]  Boxi Kang,et al.  Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing , 2017, Cell.

[29]  S. Rosenberg,et al.  Isolation of T cell receptors specifically reactive with mutated tumor associated antigens , 2014, Journal of Immunotherapy for Cancer.

[30]  S. Rosenberg,et al.  Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy , 2016, Journal of immunotherapy.

[31]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[32]  J. Gartner,et al.  Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients , 2016, Nature Medicine.

[33]  A. Drilon,et al.  Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer , 2016, Expert review of anticancer therapy.

[34]  J. Gartner,et al.  Immunogenicity of somatic mutations in human gastrointestinal cancers , 2015, Science.

[35]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[36]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[37]  P. Linsley,et al.  MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data , 2015, Genome Biology.

[38]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[39]  P. Validire,et al.  CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients , 2015, The Journal of Immunology.

[40]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[41]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[42]  D. Douek,et al.  PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. , 2014, The Journal of clinical investigation.

[43]  Åsa K. Björklund,et al.  Full-length RNA-seq from single cells using Smart-seq2 , 2014, Nature Protocols.

[44]  M. Stratton,et al.  Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[46]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[47]  F. Sánchez‐Madrid,et al.  The mitochondrial fission factor dynamin‐related protein 1 modulates T‐cell receptor signalling at the immune synapse , 2011, The EMBO journal.

[48]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[49]  S. Rosenberg,et al.  Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells , 2010, Journal of immunotherapy.

[50]  Björn Nilsson,et al.  Integrative genomic analysis of HIV-specific CD8+ T cells reveals that PD-1 inhibits T cell function by upregulating BATF , 2010, Nature Medicine.

[51]  T. Whiteside,et al.  Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. , 2009, Journal of immunological methods.

[52]  C. Bokemeyer,et al.  Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients , 2008, British Journal of Cancer.

[53]  Geoffrey E. Hinton,et al.  Visualizing Data using t-SNE , 2008 .

[54]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[55]  S. Rosenberg,et al.  High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens , 2003, The Journal of Immunology.

[56]  Yutaka Kawakami,et al.  Human tumor antigens recognized by T-cells , 1997, Immunologic research.

[57]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.